August 16, 2016
Pharmaceutical company AstraZeneca is beginning a clinical trial in collaboration with Quintiles looking at the impact of mobile medication reminders for people with chronic obstructive pulmonary disease (COPD).
The proposed yearlong trial – which is still not yet recruiting participants – will be an intervention study involving an estimated 380 people with COPD divided into two groups. Both...
August 8, 2016
MedMinder, a Needham, Massachusetts-based company that makes cellular-connected smart pill cases, has raised an additional $500,000 from an undisclosed investor. A longtime player in the connected pillbox space, MedMinder has only raised about $2.3 million in funding to date, all of it from undisclosed private investors.
The new funding will be used to support the company's recent expansion into...
June 28, 2016
HealthPrize Technologies closed a series B round of financing, which included new and existing investors. The medication adherence company intends to use the funds to expand the team both internally and internationally. While the amount of this round remains undisclosed, the company had previously raised about $7 million from investors including Mansa Capital, dLife Founder Howard Steinberg and...
June 16, 2016
Global pharmaceutical company AstraZeneca has launched a new patient-facing mobile app that includes a virtual savings card, a prescription tracker, and educational materials. The app, available in the US on the iOS App Store and Google Play store, is called AZhelps.
“AstraZeneca is committed to providing affordable medicines and programs that help patients get the support they need," Lori...
May 2, 2016
Boston's Brigham and Women’s Hospital, in partnership with Evidation Health, will test Medisafe’s medication adherence app in a randomized control trial of 390 patients taking medication for high blood pressure. Patients will be monitored with an at-home Bluetooth blood pressure cuff.
“I see patients in an acute care setting and there’s a hope that the technology will help people but it’s unclear...
April 21, 2016
HealthPrize, a Norwalk, Connecticut-based medication adherence platform company, released data this week demonstrating a 99 percent reduction in “gap days” — days between running out of a medication and filling that medication — in patients using its program.
The data comes from a cohort of 1,085 patients taking a branded cholesterol-lowering medication (HealthPrize wasn’t able to disclose which...
April 15, 2016
Redwood City, California-based digital medicine company Proteus Digital Health has raised $50 million from undisclosed investors. The company’s existing investors include Medtronic, Itochu, St. Jude Medical, and Kaiser Permanente Ventures. This brings the company’s total funding to at least $450 million.
The Proteus digital medicine platform, called Proteus Discover, is a medication management...
April 14, 2016
As we do every quarter, MobiHealthNews has rounded up our Q1 2016 coverage into a handful of longform stories. This section is on pharma. Skip ahead using these links to read Q1 digital health news roundups about providers, payers, M&A and funding.
Novartis announced a partnership with Qualcomm Life, a subsidiary of Qualcomm, to develop a connected version of its inhaler, Breezhaler...
April 8, 2016
More and more, pharma companies are making real bets in digital health, and reorganizing their businesses to put some power behind those efforts. The space is, in some ways, quieter than it was this time last year, but there’s reason to believe that quiet is a calm before a storm of activity, driven more by pharma’s tendency to keep early-stage projects close to the chest than by a lack of...
April 4, 2016
Proteus Digital Health announced interim study results from a randomized control study of its Proteus Discover timed with the American College of Cardiology event, ACC.16, in Chicago this week. The study included 96 patients with uncontrolled hypertension and type 2 diabetes and showed that a majority of the patients using the digital offering achieved the blood pressure target at week four.